Publications by authors named "Ana Sebio"

Claim this Profile
D
Diagnosis and Therapy of Soft Tissue Sarcomas: Spanish Group for Research in Sarcomas (GEIS) Guidelines.
Maria Angeles Vaz-Salgado, Claudia Valverde-Morales, Rosa Alvarez, Jose Manuel Asencio, Erica Collado, Ana Sebio

Cancers (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical practice guidelines for the treatment of Ewing sarcoma (Spanish Sarcoma Research Group-GEIS).
Cristina Mata Fernández, Ana Sebio, Javier Orcajo Rincón, Javier Martín Broto, Antonio Martín Benlloch

Clin Transl Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Spatially Fractionated Radiotherapy (LATTICE) Treatment in Inoperable Bulky Soft-Tissue Sarcomas.
Katarina Majercakova, Natalia Tejedor Aguilar, Josep Isern Verdum, Helena Vivancos Bargalló, Antonio Vila Capel, Ana Sebio

Cancers (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS).
Javier Martin-Broto, Roberto Diaz-Beveridge, David Moura, Rafael Ramos, Javier Martinez-Trufero, Ana Sebio

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab and sunitinib in patients with advanced bone sarcomas: A multicenter, single-arm, phase 2 trial.
Emanuela Palmerini, Antonio Lopez Pousa, Giovanni Grignani, Andres Redondo, Nadia Hindi, Ana Sebio

Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol.
Juliana Salazar, María J Arranz, Javier Martin-Broto, Francisco Bautista, Jerónimo Martínez-García, Ana Sebio

Pharmaceutics· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibero-American Consensus for the Management of Peritoneal Sarcomatosis: Updated Review and Clinical Recommendations.
Francisco Cristóbal Muñoz-Casares, Javier Martín-Broto, Pedro Cascales-Campos, Juan Torres-Melero, Irene López-Rojo, Ana Sebio

Cancers (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas.
Anna C Virgili, Juliana Salazar, Alberto Gallardo, Antonio López-Pousa, Raúl Terés, Ana Sebio

Diagnostics (Basel)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding the molecular landscape of undifferentiated sarcomas of bone with a novel EWSR1-SSX3 gene fusion.
Caterina Fumagalli, Ruth Orellana, Malena Ferré, Allan Gonzalez, Lluis Catasús, Ana Sebio

Genes Chromosomes Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022).
César Serrano, Rosa Álvarez, Juan Antonio Carrasco, Gloria Marquina, Jerónimo Martínez-García, Ana Sebio

Clin Transl Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS).
Jose Alejandro Pérez-Fidalgo, Eugenia Ortega, Jordi Ponce, Andres Redondo, Isabel Sevilla, Ana Sebio

Ther Adv Med Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Center Experience with Trabectedin for the Treatment of Non-L-sarcomas.
Paula Cerdà Serdà, Raúl Terés, Ana Sebio, Silvia Bagué, Ruth Orellana

Adv Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetic Profiling in High-Risk Soft Tissue Sarcomas Treated with Neoadjuvant Chemotherapy.
Anna C Virgili Manrique, Juliana Salazar, María Jesús Arranz, Silvia Bagué, Ruth Orellana, Ana Sebio

J Pers Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I.
Javier Martínez-Trufero, Josefina Cruz Jurado, M Carmen Gómez-Mateo, Daniel Bernabeu, Luis Javier Floría, Ana Sebio

Cancer Treat Rev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II.
Javier Martínez-Trufero, Josefina Cruz Jurado, C Nieves Hernández-León, Raquel Correa, Jose Manuel Asencio, Ana Sebio

Cancer Treat Rev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Gene Fusion in Solitary Fibrous Tumor: A Case Report.
David S Moura, Juan Díaz-Martín, Silvia Bagué, Ruth Orellana-Fernandez, Ana Sebio

Int J Mol Sci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Somatic Genetic Variants as Predictors of Resistance to EGFR-Targeted Therapies in Metastatic Colorectal Cancer Patients.
Pau Riera, Benjamín Rodríguez-Santiago, Adriana Lasa, Lidia Gonzalez-Quereda, Berta Martín, Ana Sebio

Cancers (Basel)· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.
Pau Riera, Alícia Artigas-Baleri, Juliana Salazar, Ana Sebio, Anna C Virgili

Front Pharmacol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors.
César Serrano, Ana Vivancos, Antonio López-Pousa, Judit Matito, Francesco M Mancuso, Ana Sebio

BMC Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
César Serrano, Xavier García-Del-Muro, Claudia Valverde, Ana Sebio, José Durán

Oncologist· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Javier Martin-Broto, Silvia Stacchiotti, Antonio Lopez-Pousa, Andres Redondo, Daniel Bernabeu, Ana Sebio

Lancet Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
David Páez, María Tobeña, Julen Fernández-Plana, Ana Sebio, Anna C Virgili

Br J Cancer· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients.
Ana Sebio, Anastasia Constantinidou, Charlotte Benson, Georgios Antoniou, Christina Messiou

Anticancer Res· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity.
Pau Riera, Juliana Salazar, Anna C Virgili, María Tobeña, Ana Sebio

Br J Clin Pharmacol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The current landscape of early drug development for patients with sarcoma in the immunotherapy era.
Ana Sebio, Breelyn A Wilky, Vicki L Keedy, Robin L Jones

Future Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis